Abstract
The public health system in Brazil is free and universal. Managers must ensure access to safe, effective and effectiveness medicines linked to the sustainability of the Health System. In 2017, the approved budget of the Specialized Component of Pharmaceutical Assistance (CEAF), responsible for purchasing over 100 drugs, was US$ 2.1 billion. Biological medicines (BM) are responsible for most of these resources. This study aims to estimate the Brazilian federal government's spending on the financing of BM for patients with spondyloarthritis: ankylosing spondylitis (AS), psoriatic arthritis (PA), ulcerative rectocolitis (UR) and Crohn's disease (CD) in the public health system.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
